What research on psoriatic arthritis to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. With thousands of research abstracts to be presented…
As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Ana-Maria Orbai, MD, MHS, associate professor of medicine and director of the Psoriatic Arthritis Program at the Johns Hopkins School of Medicine, will present a session reviewing the management of psoriatic arthritis. Dr. Orbai earned her medical degree from the Iuliu…
Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.
Emerging evidence shows COVID-19 infection may have long-term consequences, such as arthritis onset and more.
Sheldon Mark Cooper, MD, MACR, professor of medicine, and a colleague and mentor throughout my career at the University of Vermont, Burlington, passed away June 6, after a long illness. Dr. Cooper was born in The Bronx, New York, in 1942, earning his medical degree from New York University School of Medicine in 1967. He…
Axial spondyloarthritis (axSpA), comprising ankylosing spondylitis (AS) and nonradiographic axial SpA, is the main form of chronic inflammatory arthritis affecting the axial skeleton. What research in axial spondyloarthrits to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future…
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
On Sunday, Nov. 17, at ACR Convergence 2024, three speakers will deliver a presentation on Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping. This session will have three 20-minute presentations that cover distinct aspects of RA-associated ILD from early identification of ILD through high-resolution computed tomography (HRCT) text mining, to phenotyping…
In a study, all doses of LEVI-04 demonstrated significant pain relief for patients with knee osteoarthritis compared with placebo.
The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.